We show here that clozapine, a beneficial antipsychotic, down-regulates the expression of the glutamate transporter GLT-1 in the rat cerebral cortex, thereby reducing glutamate transport and raising extracellular glutamate levels. Clozapine treatment (25-35 mg kg
Introduction
Several studies suggest that glutamatergic hypofunction mediated by alterations of N-methyl-d-aspartate (NMDA) glutamate receptors may explain some features of schizophrenia. [1] [2] [3] [4] [5] [6] [7] [8] Indeed, the psychotomimetic drug phencyclidine blocks the NMDA channel 9 and mice expressing low levels of the NMDAR1 subunit display behaviors related to schizophrenia that are ameliorated by antipsychotic treatment. 6 Defective glutamatergic signaling, however, may also result from other mechanisms. High-affinity glutamate transporters (GluTs) play a pivotal role in the regulation of glutamatergic transmission, as they contribute to shaping excitatory postsynaptic responses and are essential for maintaining physiological levels of gluta-mate. 10 Among the five GluTs that have been characterized in the mammalian CNS, GLT-1, a GluT localized to distal astrocytic processes, exhibits the highest level of expression, it is responsible for the greatest proportion of total glutamate transport and its functional inactivation raises extracellular glutamate levels. 11, 12 We therefore examined whether chronic oral administration 13 of the widely used and highly effective antipsychotic clozapine 14, 15 (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) mg kg
in the drinking water) reduces the expression of GLT-1 in rats.
Materials and methods

Animals
Eighty-eight adult Sprague-Dawley rats (initial weight 190-220 g) were used. Their care and handling were approved by the Ethical Committee for Animal Research of the University of Ancona. Animals were housed 2-3 per cage, kept under a 12 h light-dark cycle (lights on at 6 am) and permitted food and water ad libitum. Experimental animals (n = 44) received cloza-pine for one (n = 4), three (n = 4), six (n = 5), nine (n = 27) or 12 (n = 4) weeks. Each group was matched to a group of control animals of the same age (n = 44). Treatment regimen, doses and length of treatment were as in Fitzgerald et al, 13 and were based on previous dosing strategies in rats 16, 17 that have been extrapolated from human clinical dosages. 13, 18 Oral clozapine administration provides more stable and continuous levels, given the reported rapid elimination of the drug 13 and its inability to accumulate in the brain. 19, 20 Clozapine (Sandoz, Basel, Switzerland) was diluted in the drinking water at 0.5 mg ml −1 (pH 6.0) as described by See and Ellison. 16 Daily dosage, calculated from drinking water intake, was between 25 and 35 mg kg ; based on previous studies in rats, 21, 22 it can be estimated that clozapine plasma levels in these experimental series ranged from 20 to 60 ng ml −1 . Daily examination revealed no observable behavioral or neurological changes besides a slight sedation during the first week of treatment. Control rats received water adjusted with diluted acetic acid to match the pH of the drug solution.
Immunohistochemistry and Western blotting
For immunohistochemistry, rats were anesthetized with chloral hydrate (300 mg kg , i.p.) and perfused by transcardial perfusion with 4% paraformaldehyde. Brains were cut in 30-m thick sections with a Vibratome; one hemisphere of each brain was cut coronally, the other parasagittally. From the former hemispheres, sections were collected from +5.2 to −6.3, and from the latter from lateral 1.4 to lateral 4.0-4.5. 23 Free-floating sections from control and experimental animals were processed as described previously 24 using affinity-purified polyclonal antibodies (0.06-0.08 g ml −1 ) against GLT-1. 25 Sections from control and treated animals were processed in parallel to minimize possible variations.
For immunoblotting, rats were perfused with cold 4 mM Tris-HCl (pH 7.4) containing 0.32 M sucrose, 1 mM EDTA, 0.5 mM phenylmethylsulphonyl fluoride (PMSF), and 0.5 mM N-ethylmaleimide (NEM). The cortical regions lying rostral to the bregma were separated from those caudal to it. The anterior and posterior cortical regions of four clozapine-treated and four control rats were separately homogenized with a glassTeflon homogenizer in 10 vol of ice-cold buffer (4 mM Tris-HCl, pH 7.4; 0.32 M sucrose; 1 mM EDTA; and 0.25 mM dithiothreitol). Homogenate processing, protein concentration determination, and protein electroblotting onto nitrocellulose filters (0.22 m) probed with antiGLT-1 antibodies (0.025 g ml −1 ) were performed as described previously. 26 Optical densities of the bands were determined using the 1.61 NIH Image analysis software. Results were normalized to GLT-1 levels in controls prepared in parallel and loaded onto the same gel. Statistical significance was evaluated by ANOVA. ; Amersham) was measured 4-5 days after injection by incubating oocytes for 1 h in frog's Ringer containing the radioisotope, at room temperature following a procedure described in a previous work. 29 Glutamate transport was calculated by subtracting the total amount of radioactivity incorporated into oocytes from that measured in the presence of the glutamate transporter inhibitor L-transpyrrolidine-2,4-dicarboxylate (500 M). Glutamate transport-induced currents were recorded 4-5 days after mRNA injection by perfusion with glutamate (1-10 mM) in the presence of the glutamate receptor antagonists D-2-amino-5-phosphonopentanoic acid (D-AP-5, 100 M), 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; 100 M) and RS-␣-methyl-4-carboxyphenylglycine (MCPG; 1 mM). All drugs were purchased from Tocris.
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Glutamate transport measurements
Microdialysis and measurement of extracellular glutamate
Rats were anesthetized with chloral hydrate (300 mg kg −1 , i.p.) and placed in a stereotaxic frame for the implantation of a transcerebral microdialysis tube across the frontal cortex (coordinates for fiber in-and out-let: 2.2 mm from the bregma and 1.9 mm from the skull surface). After at least 24 h recovery, the membranes were perfused with an iso-osmotic solution (in mM: NaCl 155, KCl 3.0, CaCl 2 2.3; pH 7.2) at a flow rate of 3.5 l min −1 . After a washout period of approximately 2 h, eight fractions were collected every 10 min to determine the basal output. The glutamate recovered in the probes was approximately 45%. The membranes were then perfused for 10 min with a solution containing 100 mM KCl (with equimolar replacement of NaCl) and then again with the control solution to monitor the recovery of basal output. At the end of the experiments, rats were anesthetized with chloral hydrate (300 mg kg −1 , i.p.) and perfused transcardially with approximately 150 ml of 4% paraformaldehyde. Brains were removed and the placement of the tubing and the presence of extensive damage was assessed on parasagittal sections. Rats displaying: (i) incorrect placement of the tubing; (ii) gross histological lesions in areas surrounding the probe path, and/or (iii) no significant increase in basal glutamate output following perfusion with 100 mM KCl were discarded from the study. Microdialysis samples were kept on ice during the collection period and stored at −20°C until assayed. Glutamate was measured by HPLC separation and fluorometric detection after precolumn derivatization with ophthalaldehyde and ethylmercaptan, as previously described. 30 Statistical significance was evaluated by performing ANOVA followed by Tukey's w test for multiple comparisons.
Results
Robust GLT-1 immunoreactivity (ir) was observed in the gray matter of control animals in most brain regions ( Figure 1 , left column) as dense punctate structures (Figure 2a and b) . In the cerebral cortex, it was present throughout the cortical mantle with a variable patchy pattern, more evident in the frontal cortex (Figure 1,  left column) .
GLT-1 ir was slightly reduced in several brain regions after 3 weeks of clozapine treatment (Figure 1 , second row) and more evidently in the animals treated for 6 weeks (Figure 1, third row) . Clozapine produced the strongest effect after 9 weeks (Figure 1, fourth row) . In rats treated for 12 weeks, clozapine-induced reduction of GLT-1 ir appeared less intense than in those treated for 9 weeks (Figure 1, fifth row) . The loss of immunostaining seemed to result from an increase of GLT-1-poor patches (Figure 2c and d) and was most evident in the cerebral cortex, although the caudateputamen, hippocampus and thalamus were also slightly affected (Figure 1) .
These data indicate that clozapine's effects on GLT-1 immunoreactivity are stronger in the cerebral cortex than in other brain regions and that they are strongest in the rats treated for 9 weeks. We therefore directed our subsequent experiments to the cerebral cortex of rats treated with clozapine for 9 weeks.
The reduction in GLT-1 immunoreactivity was intense in the frontal cortex, moderate in the frontoparietal somatic sensory and motor cortices and striate cortex (Figure 1) , and from barely detectable to absent in the auditory, cortical-amygdaloid, cingulate and retrosplenial cortices (data not shown). Immunoblotting of samples from clozapine-treated rats and from controls showed that the antiGLT-1 antibody recognized a protein with the molecular weight of about 70 kDa (Figure 3a) , consistent with the known molecular weight of GLT-1. 31 Since the observations on cortical sections suggested a stronger reduction in fronto-parietal regions, the cortical regions lying rostral to the bregma were separated from those caudal to it, and the two resulting blocks were defined anterior and posterior cortex, respectively. Densitometric analysis showed that GLT-1 protein levels were remarkably reduced in the cerebral cortex of treated rats compared to controls (Figure 3a and b) and that they were more Figure 3 Representative immunoblots of GLT-1 in the anterior (aCx) and posterior (pCx) cerebral cortex of clozapine-treated and control rats (a), and densitometric analysis of GLT-1 protein levels in immunoblots of clozapine-treated and control animals (b). Results are expressed as percentage of control (mean ± SEM). **P Ͻ 0.001; *P Ͻ 0.05 (one way ANOVA).
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severely affected in the anterior (rostral to the bregma; 71.9 ± 4.5%) than in the posterior (caudal to the bregma; 53.2 ± 15.4%) cortex (Figure 3b) . One way ANOVA analysis showed that P Ͻ 0.001 in samples from the anterior cortex and Ͻ0.05 in those from the posterior cortex.
To obtain an indirect measure of glutamate transport we injected Xenopus laevis oocytes with mRNA extracted from the anterior cerebral cortex and we evaluated the amount of L-[
3 H]-glutamate uptake. These experiments showed that in all the samples examined glutamate transport was consistently reduced in oocytes injected with extracts from rats treated for 9 weeks as compared to control animals (30.6 ± 8.6%; range 8.8-64%; seven rats; Figure 4 ). Statistical significance, determined by Fisher's protected least significant difference (PLSD) following ANOVA, was Ͻ0.01 in two out of the seven cases stud- ied and Ͻ0.001 in the remaining five (Figure 4 ). To confirm these results, we also measured the currents generated by glutamate in Xenopus laevis oocytes injected with mRNA extracted from the anterior cerebral cortex of both clozapine-treated and control animals. Electrophysiological recordings from oocytes following application of glutamate (1-10 mM) in the presence of ionotropic and metabotropic glutamate receptor antagonists revealed a strong reduction in glutamate uptake currents (46.3 ± 10.2%; range 16-62%; four rats; Figure 5a and b). Fisher PDLS test following one way ANOVA showed that P Ͻ 0.005. Altogether these results show that the efficacy of glutamate transport in rats treated with clozapine for 9 weeks is severely reduced in the anterior cortex.
We then used transverse microdialysis to study the output of glutamate from the anterior cortex of rats treated for 9 weeks with clozapine and of age-matched controls. In control rats (n = 5, 490 ± 20 g), the mean basal glutamate output (2.6 ± 0.2 M) increased to 8.1 ± 2.1 M when rats were perfused with an isoosmotic solution containing 100 mM KCl and it returned to basal levels 20 min later ( Figure 6 ). In clozapine-treated rats (n = 5, 501 ± 18 g), both the mean basal (8.1 ± 0.7 M) and the KCl-evoked (28.7 ± 7.7 M) output of glutamate were significantly elevated as compared with controls ( Figure 6 ); following KCl stimulation, glutamate initially returned to the elevated basal values but, after approximately 30 min, glutamate increased again and remained elevated (at 16.5 ± 2.8 M) until the end of the experiments ( Figure 6 ). All differences were statistically significant (see legend to Figure 6 ). These results indicate that the extracellular concentrations of glutamate under basal and depolarizing conditions are elevated in the frontal cortex of rats treated with clozapine and suggest a late impairment of glutamate reuptake following depolarization. 
Discussion
Clozapine is highly effective in the treatment of schizophrenic patients, but the full spectrum of its effects has not been detailed. Clozapine blocks several dopamine and serotonin receptors 14, 32 and facilitates NMDA receptor activity. 33 Our results demonstrate a novel effect, ie, down-regulation of GLT-1 protein expression and increase in extracellular glutamate levels in the cerebral cortex.
The temporal profile of clozapine-induced changes in GLT-1 cortical expression shows that they decline after 12 weeks of treatment. This may be related to adaptive changes occuring at glutamatergic synapses or reflect the relative reduction of clozapine levels secondary to the physiological weight gain occuring over the 9 weeks of treatment and/or, most likely, to that induced by clozapine itself. [34] [35] [36] [37] This study shows that the reduction in GLT-1 expression is uneven, with the strongest reduction being observed in the cerebral neocortex. This is consistent with the results of previous studies of clozapine's effects on glutamatergic synapses: (i) clozapineinduced up-regulation of GluR1 and GluR2 expression has been demonstrated in the prefrontal cortex but not Molecular Psychiatry in the striatum; 13 (ii) GLT-1 mRNAs in the striatum are only modestly affected by clozapine treatment; 38 and (iii) clozapine administration increases extracellular Glu levels in the prefrontal cortex but not in the striatum. 39 Overall, these data indicate that clozapine's effects on glutamatergic transmission are much stronger in the cerebral cortex than in other brain regions. In addition, clozapine effects on dopamine 40, 41 and GABA 42 levels and on c-fos induction [43] [44] [45] are significantly higher in the cerebral cortex than in subcortical regions; taken together these data support the hypothesis that the cerebral cortex is the preferential site for clozapine action. 46 Although we did not perform a systematic analysis of GLT-1 protein reduction in all cortical areas, the present results document that the effects of clozapine are strongest in cortical regions located rostral to the bregma. Since clozapine-induced changes in AMPA receptor subunits 13, 47 and Glu levels 39 are also more pronounced in the frontal regions, it is conceivable that clozapine's action on glutamatergic, as on dopaminergic and GABAergic (see above), transmission is more intense in the frontal neocortex.
Given that a considerable amount of data indicate that some of the symptoms of schizophrenia may be subtended by a reduced efficacy of glutamatergic transmission [1] [2] [3] [4] [5] [6] [7] [8] (see however Moghaddam and Adams 48 ), our results suggest that clozapine exerts at least partly its therapeutic effect by reducing glutamate transport and raising extracellular glutamate levels. Although application of data from rodents to a complex human disease requires caution, the present data suggest for the first time that glutamatergic hypofunction in schizophrenia may partly result from changes in GLT-1 expression and/or activity.
